GlassScriptPhysician profile
Lindsey M Olson
NPI 1396951356
$781.22
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $201.80 | 2019-2020 | |
| Amgen INC. | $89.39 | 2019-2020 | |
| Novo Nordisk INC | $87.78 | 2019-2020 | |
| Pfizer INC. | $68.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.88 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $51.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.63 | 2019-2020 | |
| Genentech USA, INC. | $37.04 | 2019 | |
| Lilly USA, LLC | $23.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.90 | 2020 | |
| Abbott Laboratories | $14.62 | 2019 | |
| Cranial Technologies, INC | $14.24 | 2020 | |
| Glaxosmithkline, LLC. | $13.51 | 2019 | |
| Avion Pharmaceuticals | $13.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $11.81 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.